Reem Al-Olaby

Title: Reem Al-Olaby: Innovator in Therapeutic Ligands

Introduction

Reem Al-Olaby is a prominent inventor based in Cairo, Egypt. She has made significant contributions to the field of therapeutic methods through her innovative research. Her work focuses on ligands that target sporozoite binding sites on CD81, which has important implications for treating infections.

Latest Patents

Reem Al-Olaby holds a patent for her invention titled "Ligands that target sporozoite binding sites on CD81 and therapeutic methods using them." This invention pertains to ligands that bind to CD81 and inhibit or block attachment to this protein. The patent outlines compositions and methods for preventing, inhibiting, or treating infections by targeting binding sites on CD81. Through her research, she has identified several important ligand binding sites on the large extracellular loop of the open conformation of CD81. By linking together ligands that bind with low or moderate affinities to different structurally unique sites, she has generated small molecule ligand conjugates that exhibit very high affinities to their CD81 targets.

Career Highlights

Reem Al-Olaby is affiliated with the American University in Cairo, where she conducts her research and development. Her work has been instrumental in identifying and designing compounds that bind to CD81 for therapeutic use. These compounds can block attachment and entry into cells, inhibit inflammatory responses, and prevent the induction of other pathologies associated with infections.

Collaborations

Reem has collaborated with notable colleagues, including Hassan Azzazy and Rodney L Balhorn. Their combined expertise has contributed to the advancement of research in therapeutic ligands.

Conclusion

Reem Al-Olaby's innovative work in the field of therapeutic ligands showcases her dedication to advancing medical science. Her contributions have the potential to significantly impact the treatment of infections and improve patient outcomes.